Drugs / Immunomodulatory DC vaccines
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07068555 | Jun 2025 → Jun 2028 expected | — | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Immunomodulatory DC vaccines | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07068555 ↗ |
| Modality | Vaccine | “prostate cancer DC vaccines” NCT07068555 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT07068555 ↗ |